ArticleInfection and drug resistance2026
Treatment Bundle for Bloodstream Infection Caused by Carbapenem-Resistant
Article in Infection and drug resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Bloodstream infection (BSI) caused by carbapenem-resistant Patients and methods: Among 728 LT recipients, 25 patients with CRKP BSIs were included. The CCBT comprised: (1) prompt infection source control; (2) early ceftazidime-avibactam initiation (<3 days post-culture); (3) immunosuppression adjustment (discontinuation of calcineurin/mechanistic target of rapamycin inhibitors/mycophenolate until blood culture clearance); and (4) intravenous immunoglobulin (IVIG, 300 mg/kg/day for 5 days). The controls received empirical anti-infection therapy comprising polymyxin- and tigecycline-based combination regimens, or amikacin and polymyxin used in combination with meropenem according to drug susceptibility results. Outcomes included microbiological clearance, mortality, immune/liver function recovery, recurrence, and complications. Results: Patients were distributed into CCBT (n=15) and control (n=10) groups. The CCBT group had a higher blood culture clearance rate (100% vs 50%; Conclusion: A multidisciplinary bundle integrating ceftazidime-avibactam, IVIG and immunosuppression minimization significantly improved survival and microbiological outcomes in patients with CRKP BSI after LT, compared with antibiotic therapy alone. Multicenter studies are merited to confirm whether wider implementation of this multidisciplinary bundle would improve outcomes in patients with CRKP BSI after LT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.